# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| I |                    |           |
|---|--------------------|-----------|
|   | OMB Number:        | 3235-0287 |
|   | Estimated average  | burden    |
|   | hours per response | : 0.5     |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Addre<br>Satter Mune       | ess of Reporting Per<br><u>er A</u> | son*  | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br>Annexon, Inc. [ ANNX ] |   | ationship of Reportin<br>k all applicable)<br>Director | g Persoi<br>X | on(s) to Issuer<br>10% Owner |  |
|--|-------------------------------------|-------|--|---|--|---------------|------------------------------|--|
| (Last)<br>C/O ANNEXO                   |                                     |       | 3. Date of Earliest Transaction (Month/Day/Year)<br>02/10/2023               |   | Officer (give title below)                             |               | Other (specify<br>below)     |  |
| 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR |                                     |       | 4. If Amendment, Date of Original Filed (Month/Day/Year)                     | 6. Individual or Joint/Group Filing (Check Applicable Line) |  |               |                              |  |
| (Street)<br>BRISBANE                   | CA                                  | 94005 |  | X   | Form filed by One<br>Form filed by Mor<br>Person       | •             | 0                            |  |
| (City)                                 | (State)                             | (Zip) |  |   |  |               |                              |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Transaction D<br>Code (Instr. |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |               | Securities                         |   | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|-------------------------------|---|--|---------------|---------------|------------------------------------|---|---|
|                                 |  |   | Code                          | v | Amount   | (A) or<br>(D) | Price         | Transaction(s)<br>(Instr. 3 and 4) |   | (1150.4)  |
| Common Stock                    | 02/10/2023                                 |   | Р                             |   | 2,647,058(1)   | A             | \$ <u>6.8</u> | 7,056,024                          | Ι | See<br>footnote <sup>(2)</sup>                                    |

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

|   |   |  | ( 0/1   | ,                            | , |   | ,   | • •                 |   |       |   | ,  |  |  |  |
|---|---|--|---|------------------------------|---|---|-----|---------------------|---|-------|---|--|--|--|--|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | 5. Number<br>of Expiration Date<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3, 4<br>and 5) |     | ate                 | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr.<br>3 and 4) |       | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|   |   |  |   | Code                         | v | (A)   | (D) | Date<br>Exercisable | Expiration<br>Date  | Title | Amount<br>or<br>Number<br>of<br>Shares              |  |  |  |  |

#### Explanation of Responses:

1. All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

2. Includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 5,101,046 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power of all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest.

| /s/ Muneer A. Satter             |  |
|----------------------------------|--|
| ** Cignoture of Deporting Dereon |  |

Signature of Reporting Person

02/14/2023 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.